Zai Lab Stock Investor Sentiment
| ZLAB Stock | USD 18.34 -0.53 -2.81% |
About 74% of Zai Lab's investor base is looking to short. The analysis of the overall investor sentiment regarding Zai Lab suggests that many traders are alarmed. The current market sentiment, together with Zai Lab's historical and current headlines, can help investors time the market. In addition, many technical investors use Zai Lab stock news signals to limit their universe of possible portfolio assets.
Investor Comfort Level
Alarmed
Panic | Confidence |
Zai Lab Maximum Pain Price Across 2026-06-18 Option Contracts
Reviewing maximum pain in Zai Lab can add context around short-term options sentiment, especially when open interest becomes concentrated near a narrow range of strikes. This is most valuable when investors treat options positioning as one component of market context instead of as a complete explanation for price movement.
Sentiment analytics for Zai Lab matter because the market regularly prices narrative, confidence, and fear alongside operating data. The goal is to add context around perception and momentum, not to replace valuation, earnings, or risk analysis.
News SentimentNeutral | Hype SentimentBearish | Insider SentimentDisposing |
Zai Historical Sentiment
Although Zai Lab's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained.
Zai Lab Sentiment by Major News Outlets
Reviewing outlet-level tone around Zai Lab gives investors a practical way to compare how the same company is being interpreted across the news landscape. The stronger process compares outlet tone with price behavior and the quality of the underlying catalyst instead of assuming that any publisher is directionally correct.
Investor sentiment can influence Zai Lab materially, but it still sits beside fundamentals, industry trends, and macro conditions rather than replacing them. This perspective is most useful when investors need to understand why price is moving faster than the business itself.
Zai Lab Historical Investor Sentiment
Looking back at sentiment trends in Zai Lab can improve analysis when investors want to see whether optimism or caution has been building gradually or changing abruptly. The point is to understand how public conviction evolves, not to assume that every change in tone should trigger a trade.
The daily sentiment pattern around Zai Lab reflects aggregated mention quality rather than one article or one outlet. The stronger use of this data is comparative: investors can see when tone improved, when it deteriorated, and whether that shift aligned with the market reaction.
Investors tracking Zai Lab usually watch the news flow closely because earnings narrative, macro context, and company-specific updates can all affect near-term trading behavior. The better read comes from comparing headlines with earnings quality, analyst revisions, and the broader market backdrop rather than reacting to one isolated story. Current markets are slightly bearish. About 56% of major world exchanges and indexes are down. See today's market update for more information.
Headline and social activity around Zai Lab can be extensive across public sources. This module organizes Zai Lab's coverage into a structured view for context.
News analysis reviews whether price behavior aligns with recent headlines and attention signals. It focuses on headline history and attention patterns around Zai Lab.
Largest EPS Surprises
Earnings surprises can materially move Zai Lab's market value. Misses often reprice quickly; beats can support follow-through. For this stock, read EPS surprises with profitability quality and forward revisions.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2018-11-28 | 2018-09-30 | -0.4 | -0.33 | 0.07 | 17 | ||
2025-11-06 | 2025-09-30 | -0.25 | -0.33 | -0.08 | 32 | ||
2026-02-26 | 2025-12-31 | -0.3712 | -0.46 | -0.0888 | 23 | ||
2024-08-06 | 2024-06-30 | -0.71 | -0.8 | -0.09 | 12 | ||
2020-03-19 | 2019-12-31 | -0.59 | -0.68 | -0.09 | 15 | ||
2025-05-06 | 2025-03-31 | -0.5475 | -0.45 | 0.0975 | 17 |
Headline and social activity around Zai Lab can be extensive across public sources. This module organizes Zai Lab's coverage into a structured view for context.
News analysis reviews whether price behavior aligns with recent headlines and attention signals. It focuses on headline history and attention patterns around Zai Lab.
Stock Overview, Methodology & Data Sources
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China. Zai Lab operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1951 people. The stock overview for Zai Lab summarizes business drivers, financial profile, and market behavior. The company is positioned within Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Current metrics include P/B of 2.95, profit margin of -38.15%. Zai Lab has a market cap of 2.11 B, ROE of -22.56%.
Methodology
Unless otherwise specified, financial data for Zai Lab is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Zai (USA Stocks:ZLAB) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Datasets used in this report incorporate public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Information may be standardized across formats and may reflect delayed updates. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Zai Lab is covered by 11 analysts. 5 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Bernstein Research, Deutsche Bank, Morgan Stanley, BMO Capital Markets, Guggenheim Securities, Jefferies, among others. Updates may occur throughout the day.
This content is curated and reviewed by:
Ellen Johnson - Member of Macroaxis Editorial BoardZai Lab Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 8651 shares by Edmondson Frazor Titus Iii of Zai Lab at 17.14 subject to Rule 16b-3 | 12/16/2025 |
2 | How Investors May Respond To Zai Lab Advancing ZL-1503 Into Global Phase 11b Atopic Dermatitis Trial | 12/19/2025 |
3 | Disposition of 21000 shares by Amado Rafael of Zai Lab subject to Rule 16b-3 | 12/30/2025 |
4 | Disposition of 10787 shares by Amado Rafael of Zai Lab at 17.432 subject to Rule 16b-3 | 12/31/2025 |
5 | How Investors May Respond To Zai Lab Winning Expanded China Approval For AUGTYRO Cancer Therapy | 01/15/2026 |
6 | Acquisition by Gaynor Richard of 10831 shares of Zai Lab subject to Rule 16b-3 | 01/22/2026 |
7 | Zai Lab sets Feb. 26 webcast on 2025 results and corporate updates - Stock Titan | 02/10/2026 |
8 | Zai Lab Q4 2025 Earnings Preview | 02/25/2026 |
9 | Zai Lab outlines 2026 transition year with multiple late-stage catalysts and targets first global approval by 2028 | 02/26/2026 |
10 | Zai Lab Announces Quarterly Earnings Results, Misses Estimates By 0.02 EPS | 02/27/2026 |
11 | Disposition of 10000 shares by Amado Rafael of Zai Lab at 17.38 subject to Rule 16b-3 | 03/03/2026 |
12 | Disposition of 50000 shares by Ying Du of Zai Lab at 1.74 subject to Rule 16b-3 | 03/04/2026 |
13 | How Investors Are Reacting To Zai Lab Narrowing Losses Amid Rising Q4 2025 Revenue | 03/06/2026 |
14 | Disposition of 2655 shares by Ying Du of Zai Lab subject to Rule 16b-3 | 03/10/2026 |
15 | Disposition of 1067 shares by Ying Du of Zai Lab at 19.084 subject to Rule 16b-3 | 03/11/2026 |
Popular Tools for Zai Stock analysis
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |